Silk Road Medical Q1 2024 revenue $48.5M (+21% YoY); net loss narrows to $14.1M

Silk Road Medical Inc

2024-Q1 EPS reported -$0.36 revenue$48,484,000

Revenue $48.5M, up 21% YoY driven by increased TCAR adoption.
Gross margin 75%, up from 69% YoY due to favorable production variances.
Net loss $14.1M ($0.36/share) vs $16.5M ($0.43/share) in Q1 2023.
Adjusted EBITDA loss improved to $3.9M from $7.4M in Q1 2023.
CEO cites commercial progress and steps toward sustainable profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Silk Road Medical Inc reported the three months ended March 31, 2024 results: revenue $48.5 million, EPS $0.36 per share.

Period: the three months ended March 31, 2024
Revenue: $48.5 million
EPS: $0.36 per share
Result: preliminary results

Exact text from the filing

and patients and in our opportunity to drive strong, sustainable growth as a business.” First Quarter 2024 Financial Results Revenue for the first quarter of 2024 was $48.5 million, an increase of $8.4 million or 21%, compared to the first quarter of 2023. Growth was driven primarily by increased TCAR adoption. Gross profit for the first quarter of 2024

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001397702-24-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.